Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

21. Alzheimer's dementia

Alzheimer's dementia Alzheimer's dementia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Alzheimer's dementia Last reviewed: August 2018 Last updated: September 2018 Summary Chronic, progressive neurodegenerative disorder characterised by a global, non-reversible impairment in cerebral functioning. Characterised by memory loss, loss of social and occupational functioning, diminished executive function, speech (...) support groups are beneficial to caregivers and should be considered, where available. Definition Alzheimer's disease (AD) is a chronic neurodegenerative disease with an insidious onset and progressive but slow decline. AD is the most common type of dementia. Grossman H, Bergmann C, Parker S. Dementia: a brief review. Mt Sinai J Med. 2006 Nov;73(7):985-92. http://www.ncbi.nlm.nih.gov/pubmed/17195884?tool=bestpractice.com Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population

BMJ Best Practice2018

22. Modifiable pathways in Alzheimer's disease: Mendelian randomisation analysis.

Modifiable pathways in Alzheimer's disease: Mendelian randomisation analysis. OBJECTIVE: To determine which potentially modifiable risk factors, including socioeconomic, lifestyle/dietary, cardiometabolic, and inflammatory factors, are associated with Alzheimer's disease. DESIGN: Mendelian randomisation study using genetic variants associated with the modifiable risk factors as instrumental variables. SETTING: International Genomics of Alzheimer's Project. PARTICIPANTS: 17 008 cases (...) of Alzheimer's disease and 37 154 controls. MAIN OUTCOME MEASURES: Odds ratio of Alzheimer's per genetically predicted increase in each modifiable risk factor estimated with Mendelian randomisation analysis. RESULTS: This study included analyses of 24 potentially modifiable risk factors. A Bonferroni corrected threshold of P=0.002 was considered to be significant, and P<0.05 was considered suggestive of evidence for a potential association. Genetically predicted educational attainment was significantly

BMJ2017 Full Text: Link to full Text with Trip Pro

23. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer`s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial

Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer`s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial 28945120 2017 09 25 1535-7228 2017 Sep 15 The American journal of psychiatry Am J Psychiatry Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. appiajp201717030316 10.1176/appi.ajp.2017.17030316 Apathy is a common behavioral problem in Alzheimer's (...) disease. Apathy has profound consequences, such as functional impairment, higher service utilization, higher caregiver burden, and increased mortality. The authors' objective was to study the effects of methylphenidate on apathy in Alzheimer's disease. A 12-week, prospective, double-blind, randomized, placebo-controlled trial (methylphenidate versus placebo) was conducted in community-dwelling veterans (N=60) with mild Alzheimer's disease. The primary outcome for apathy (Apathy Evaluation Scale

EvidenceUpdates2017

24. Alzheimer’s Patients Deserve Death with Dignity - VSED

Alzheimer’s Patients Deserve Death with Dignity - VSED Alzheimer’s Patients Deserve Death with Dignity - VSED - Medicalvideos Breaking News Fetching data... ☰ Navigation Unlabelled Alzheimer’s Patients Deserve Death with Dignity - VSED Jumat, 17 November 2017 End of Life Washington recently drafted “ ,” similar to an advance directive, a document which expresses a person’s decision about when to be offered food and fluids during late-stage dementia. EOLWA board member Robert Free has an op-ed (...) explaining the new instrument in . Alzheimer’s Patients Deserve Death with Dignity - VSED BojakHom 2017-11-17T15:51:00-08:00 5.0 stars based on 35 reviews End of Life Washington recently drafted “ Instructions for Oral Feeding and Drinking ,” similar to an advance directive, a document which ex... SUBSCRIBE TO OUR NEWSLETTER Related Posts Load disqus comments 0 komentar Langganan: Popular Posts A Coverdell Education Savings Accounts (ESA) is a believe or custodial account designed to assist households

MedicalVideos2017

25. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). BACKGROUND: 18 F-florbetaben uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18 F-florbetaben. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18 F-florbetaben

Cochrane2017

26. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). BACKGROUND: 18 F-flutemetamol uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and the confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18 F-flutemetamol. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18 F-flutemetamol

Cochrane2017

27. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer

Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer 28841388 2017 08 25 2017 10 30 2017 11 02 1527-7755 35 30 2017 Oct 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer. 3401-3409 10.1200/JCO.2017.72.6109 Purpose To assess the relative (...) risk of Alzheimer's disease (AD) among patients with prostate cancer who received androgen deprivation therapy (ADT), after adjustment for other cancer therapies. Methods Data from demographics, survival, diagnoses codes, procedure codes, and other information about beneficiaries age 67 years or older in the Medicare claims database was assessed to determine the unadjusted and adjusted risks of AD and of dementia from ADT. The prespecified survival analysis method was competing risk regression

EvidenceUpdates2017

28. Alzheimer?s Disease: State of Diagnosis

Alzheimer?s Disease: State of Diagnosis Alzheimer’s Disease: State of Diagnosis | Clinical Correlations Alzheimer’s Disease: State of Diagnosis October 4, 2017 By Karen McCloskey, MD Peer Reviewed In May 2012, The U.S. Department of Health and Human Services unveiled the “National Plan to Address Alzheimer’s Disease,” in response to legislation signed by President Obama in January, 2011 establishing the National Alzheimer’s Project Act. The overarching goal of the Plan is to “prevent (...) or effectively treat Alzheimer’s Disease by 2025.” We now have an estimated 5.5 million people who are living with this illness[1] and these numbers are only expected to grow with the aging [2]. The U.S. Preventive Services Task Force finds no evidence to recommend widespread dementia screening[3], however the Affordable Care Act requires an annual cognitive assessment for all Medicare enrollees. It is troublesome that, in one study 55% of cases of dementia went unrecognized by patients’ primary

Clinical Correlations2017

29. The Association Between the Use of Zolpidem and the Risk of Alzheimer`s Disease Among Older People

The Association Between the Use of Zolpidem and the Risk of Alzheimer`s Disease Among Older People 28884784 2017 09 08 2017 09 08 1532-5415 2017 Sep 07 Journal of the American Geriatrics Society J Am Geriatr Soc The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People. 10.1111/jgs.15018 To evaluate the association between zolpidem use and the risk of Alzheimer's disease among older people. A retrospective cohort study using data from 2001 to 2011 from (...) as: less than 28, 28-90, 91-180, and more than 180 cDDD). The occurrence of Alzheimer's disease was defined as the time period from the end of one year after the index date to the date of the Alzheimer's disease diagnosis. The propensity score was used to adjust the measured confounders of Alzheimer's disease. Cox proportional hazards models were used to evaluate the association between zolpidem use and the incidence of Alzheimer's disease. Zolpidem users with a high cumulative dose (>180 cDDD

EvidenceUpdates2017

30. Positron Emission Tomography (PET) for Alzheimer disease

Positron Emission Tomography (PET) for Alzheimer disease Positron Emission Tomography (PET) for Alzheimer disease Positron Emission Tomography (PET) for Alzheimer disease HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Positron Emission Tomography (PET) for Alzheimer disease. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors (...) ' conclusions Positron emission tomography (PET) is a 3-dimensional (3D) nuclear imaging technique that measures the level of physiologic and biochemical activity or other organic function in an organ or tissue by reflecting the distribution of a radiotracer that has been administered to the patient. PET has been proposed as a method for diagnosing and predicting development of Alzheimer disease (AD). Relevant Questions: Is PET an accurate diagnostic test for detection or prediction of the development of AD

Health Technology Assessment (HTA) Database.2017

31. Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis

Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis 28655175 2017 06 28 2017 06 28 1468-2834 2017 Jun 24 Age and ageing Age Ageing Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis. 1-7 10.1093/ageing/afx098 dementia is increasingly recognised as life-limiting condition. Although the benefits of acetylcholinesterase (...) inhibitors (AChEIs) on cognition and function are well established, their effect on survival is less clear. to investigate associations between AChEI prescription and mortality in patients with Alzheimer's dementia (AD) in a naturalistic setting, using detailed baseline data on cognition, functioning, and mental and physical wellbeing. we used a large mental healthcare database in South London, linked to Hospital Episode Statistics and Office for National Statistics mortality data, to assemble

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

32. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease

No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease 28695906 2017 07 11 2017 07 11 1572-0241 2017 Jul 11 The American journal of gastroenterology Am. J. Gastroenterol. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease. 10.1038/ajg.2017.196 The objective of the study was to investigate whether proton pump inhibitor (PPI) use is associated with an increased risk of clinically verified Alzheimer's disease (AD). A Finnish nationwide nested

EvidenceUpdates2017

33. Physical activity and beta-amyloid pathology in Alzheimer's disease: A sound mind in a sound body

Physical activity and beta-amyloid pathology in Alzheimer's disease: A sound mind in a sound body 28900376 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Physical activity and beta-amyloid pathology in Alzheimer's disease: A sound mind in a sound body. 959-972 10.17179/excli2017-475 Alzheimer's disease (AD) is the most common type of dementia worldwide. Since curative treatment has not been established for AD yet and due to heavy financial and psychological costs of patients' care, special (...) , School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. Sadigh-Eteghad Saeed S Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. eng Journal Article Review 2017 06 28 Germany EXCLI J 101299402 1611-2156 Alzheimer's disease beta-amyloid physical activity prevention 2017 05 19 2017 06 17 2017 9 14 6 0 2017 9 14 6 0 2017 9 14 6 1 epublish 28900376 10.17179/excli2017-475 2017-475 Doc959 PMC5579405 J Appl Physiol (1985). 2015 Nov 15;119(10 ):1097-104

EXCLI journal2017 Full Text: Link to full Text with Trip Pro

34. Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia

Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P, Jutkowitz E, McCreedy E, Nelson VA, McCarten JR, Calvert C, Ratner E, Hemmy (...) LS, Barclay T Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P, Jutkowitz E, McCreedy E, Nelson VA, McCarten JR, Calvert C, Ratner E, Hemmy LS, Barclay T. Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia. Rockville: Agency for Healthcare

Health Technology Assessment (HTA) Database.2017

35. A phase 3 trial of IV immunoglobulin for Alzheimer disease

A phase 3 trial of IV immunoglobulin for Alzheimer disease 28381506 2017 04 06 2017 05 11 1526-632X 88 18 2017 May 02 Neurology Neurology A phase 3 trial of IV immunoglobulin for Alzheimer disease. 1768-1775 10.1212/WNL.0000000000003904 We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia. In a phase 3, double-blind, placebo-controlled trial, we randomly assigned 390 participants with mild to moderate AD to receive (...) placebo (low-dose albumin) or IVIg (Gammagard Liquid; Baxalta, Bannockburn, IL) administered IV at doses of 0.2 or 0.4 g/kg every 2 weeks for 18 months. The primary cognitive outcome was change from baseline to 18 months on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale; the primary functional outcome was 18-month change on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory. Safety and tolerability data, as well as serial MRIs and plasma samples

EvidenceUpdates2017

36. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease

Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease 28396328 2017 04 11 2017 04 19 2017 04 19 1488-2329 189 14 2017 Apr 10 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. E519-E529 10.1503/cmaj.160126 Knowledge regarding whether benzodiazepines and similarly acting (...) non-benzodiazepines (Z-drugs) are associated with an increased risk of pneumonia among older adults is lacking. We sought to investigate this association among community-dwelling adults with Alzheimer disease, a condition in which both sedative/hypnotic use and pneumonia are common. We obtained data on all community-dwelling adults with a recent diagnosis of Alzheimer disease in Finland (2005-2011) from the Medication use and Alzheimer disease (MEDALZ) cohort, which incorporates national registry

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

37. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer`s disease: a Phase II multicenter randomised controlled trial

Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer`s disease: a Phase II multicenter randomised controlled trial 28419192 2017 04 18 2017 04 18 1468-2834 2017 Apr 17 Age and ageing Age Ageing Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial. 1-7 10.1093/ageing/afx045 inhibition of acetylcholinesterase (...) (AChE) has been a effective treatment for Alzheimer's disease (AD). Octohydroaminoacridine, a new AChE inhibitor, is a potential treatment for AD. we conducted a multicenter, randomised, double blind, placebo-controlled, parallel-group Phase II clinical trial to investigate the effects of octohydroaminoacridine in patients with mild-to-moderate AD. Patients were randomised to receive placebo thrice daily, octohydroaminoacridine 1 mg/thrice daily (TID) (low-dose group), 2 mg/TID (middle-dose group

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

38. Low LDL cholesterol, <i>PCSK9</i> and <i>HMGCR</i> genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. Objective To test the hypothesis that low density lipoprotein (LDL) cholesterol due to genetic variation in the genes responsible for LDL cholesterol metabolism and biosynthesis( PCSK9 and 3-hydroxy-3-methylglutaryl-CoA reductase ( HMGCR ), respectively) is associated with a high risk of Alzheimer's disease, vascular dementia, any dementia (...) , and Parkinson's disease in the general population. Design Mendelian randomisation study. Setting Copenhagen General Population Study and Copenhagen City Heart Study. Participants 111 194 individuals from the Danish general population. Main outcome measures Risk of Alzheimer's disease, vascular dementia, all dementia, and Parkinson's disease. Results In observational analyses, the multifactorially adjusted hazard ratio for Parkinson's disease in participants with an LDL cholesterol level <1.8 mmol/L versus

BMJ2017 Full Text: Link to full Text with Trip Pro

39. Vitamin E for Alzheimer's dementia and mild cognitive impairment.

Vitamin E for Alzheimer's dementia and mild cognitive impairment. BACKGROUND: Vitamin E occurs naturally in the diet. It has several biological activities, including functioning as an antioxidant to scavenge toxic free radicals. Evidence that free radicals may contribute to the pathological processes behind cognitive impairment has led to interest in the use of vitamin E supplements to treat mild cognitive impairment (MCI) and Alzheimer's disease (AD). This is an update of a Cochrane Review (...) extract outcome data in accordance with our protocol from two trials, one in an AD population (n = 304) and one in an MCI population (n = 516). Both trials had an overall low to unclear risk of bias. It was not possible to pool data across studies owing to a lack of comparable outcome measures.In people with AD, we found no evidence of any clinically important effect of vitamin E on cognition, measured with change from baseline in the Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog

Cochrane2017

40. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia

Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia Comparative Effectiveness Review Number 188 Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia eComparative Effectiveness Review Number 188 Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia Prepared for: Agency for Healthcare Research (...) @ahrq.hhs.gov. Suggested citation: Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P, Jutkowitz E, McCreedy E, Nelson VA, McCarten JR, Calvert C, Ratner E, Hemmy LS, Barclay T. Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia. Comparative Effectiveness Review No. 188. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2015-00008-I.) AHRQ Publication No. 17-EHC008-EF. Rockville, MD: Agency

Effective Health Care Program (AHRQ)2017